Extinction Learning in Adults With Tourette Syndrome
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04498364 |
Recruitment Status :
Recruiting
First Posted : August 4, 2020
Last Update Posted : September 9, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Tourette Syndrome Habit Reversal Training Tic Disorders Tics Comprehensive Behavioral Intervention for Tics | Behavioral: Habit Reversal Training | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 50 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Extinction Learning in Adults With Tourette Syndrome |
Actual Study Start Date : | September 18, 2020 |
Estimated Primary Completion Date : | September 30, 2023 |
Estimated Study Completion Date : | September 30, 2023 |

Arm | Intervention/treatment |
---|---|
Experimental: Habit Reversal Training
Habit Reversal Training (HRT) is a multi-component evidence-based treatment for tics. It will be delivered over 8 hours of treatment.
|
Behavioral: Habit Reversal Training
Habit Reversal Training (HRT) is a multi-component evidence-based treatment for tics. |
- Tic severity as assessed by the Hopkins Motor and Vocal Tic Scale (HM/VTS) [ Time Frame: Within 1 week after completion of HRT ]Patient will nominate up to five motor and five vocal tics they deem bothersome on the HM/VTS. Each bothersome tic is then rated by a clinician on the composite two (vocal and motor) 5-point HM/VTS scale ranging from none (0) to severe (4) for the motor as well as vocal tics. The individual tic scores are summed (minimum of 0 and maximum of 40) and averaged together to create an average tic severity score.
- Tic severity as assessed by the Yale Global Tic Severity Scale-Revised (YGTSS) [ Time Frame: Within 1 week after completion of HRT ]The YGTSS is a clinician-rated semi-structured interview that measures tic symptom severity over the previous week. It consists of 10-items that assess different dimensions of tic severity for motor and vocal tics, which are rated on a 0-5 scale. The YGTSS produces a Total Tic Score (range: 0-50), with higher ratings indicating greater tic severity. The YGTSS has demonstrated treatment sensitivity to pharmacotherapy and behavioral interventions.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- At least 18 years old,
- Have moderate tic severity or greater as evidenced by a YGTSS Total Tic Score greater than 13 (>9 for youth with motor or vocal tics only)
- Have not received more than 4 previous sessions of HRT
- Be fluent in English
- Medication free or on a stable dose of psychiatric medication for 8 weeks prior to enrollment.
Exclusion Criteria:
- An inability to complete rating scales
- An inability to attend study visits

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04498364
Contact: Nicholas Myers | 4432877157 | coach@jhmi.edu |
United States, Maryland | |
Johns Hopkins University School of Medicine | Recruiting |
Baltimore, Maryland, United States, 21205 | |
Contact: Nicholas Myers, M.A 443-287-7157 coach@jhmi.edu | |
Principal Investigator: Joseph McGuire, PhD |
Principal Investigator: | Joseph F McGuire, PhD | Johns Hopkins University |
Responsible Party: | Johns Hopkins University |
ClinicalTrials.gov Identifier: | NCT04498364 |
Other Study ID Numbers: |
IRB00256962 |
First Posted: | August 4, 2020 Key Record Dates |
Last Update Posted: | September 9, 2022 |
Last Verified: | September 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Extinction Learning Comprehensive Behavioral Intervention for Tics Behavior Therapy Habit Reversal Training Tourette's Disorder |
Tourette Syndrome Tic Disorders Syndrome Disease Pathologic Processes Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Movement Disorders Heredodegenerative Disorders, Nervous System Neurodegenerative Diseases Genetic Diseases, Inborn Neurodevelopmental Disorders Mental Disorders |